1. What Happened? SunBio’s Q2 2025 Earnings Report Breakdown

SunBio reported KRW 4.74 billion in revenue (a 36.5% YoY increase) and achieved operating profit in Q2 2025. However, the company still recorded a net loss of KRW 570 million.

2. Why These Results? Analyzing the Positive and Negative Factors

  • Positive Factors:
    • Increased production capacity from the new plant
    • Solid growth in the PEG derivative business
    • Expansion of biosimilar business into overseas markets
  • Negative Factors:
    • Continued net loss due to high R&D and SG&A expenses
    • Decreased cash and increased debt ratio (130.32%) due to new plant construction and treasury stock acquisition
    • Uncertainty surrounding new businesses (all-solid-state battery electrolytes and artificial blood)

3. What’s Next? Future Outlook and Investment Strategy

SunBio’s future hinges on FDA approval for its Pegfilgrastim biosimilar, MucoPEG™ sales performance in the US market, and successful commercialization of its new businesses. While long-term growth potential exists, a cautious investment approach is warranted given the potential for financial instability and uncertainties related to new ventures.

4. Investor Action Plan: Key Investment Points and Monitoring Factors

  • Monitor FDA approval progress and sales channel expansion
  • Track the progress of technology development and commercialization of new businesses
  • Keep an eye on the timing of net profit turnaround and improvements in financial structure